Biogen Idec - Too High Too Fast? Seeking Alpha Daclizumab-HYP Phase III data readout expected in 2014. It is also for relapsing forms of MS. Biogen also filed for approval with FDA for Hemophilia Factor 8 for A and 9 for B, based on significant Phase III trial results. A number of other therapies ... |
